Articles by Tag #flowcytometry
Browse our collection of articles on various topics related to IT technologies. Dive in and explore something new!
Millions of Flow Cytometry Datasets Are Useless for AI — Here's Why, and What It Would Take to Fix It
NIST, FDA, and NIAID convened a first-of-its-kind workshop to address a crisis hiding in plain sight: millions of flow cytometry datasets are unusable for AI. We traced the evidence trail from 211,359
We're Building Agentic Flow Cytometry Analysis — Here's Why Nobody Else Is
A thoracic surgeon and his AI agent searched PubMed for "agentic flow cytometry" — and found nothing. Zero papers. That gap isn't a dead end; it's the opportunity. Here's what we found when we dug dee
The 36-Marker Problem: Why Next-Day CAR-T Manufacturing Will Break Without AI-Driven Spectral Flow Cytometry
A 36-marker spectral panel can predict CAR-T product quality. Next-day manufacturing needs QC in hours. Manual analysis takes days. The math doesn't work — unless AI closes the gap. Part 7 of the Flow
GMM+Fisher Vector+SVM vs. Agentic AI: Two Philosophies of Flow Cytometry Automation
AHEAD Medicine's patented GMM→Fisher Vector→SVM pipeline achieves 98% accuracy in AML diagnosis. Flow Monkey's agentic approach reasons through novel panels without retraining. We dissect both archite
Fisher Vector Deep Dive: How a 2007 Image Classification Method Powers Today's Most Accurate Flow Cytometry AI
Fisher Vector encodes how data deviates from a generative model by computing gradients of log-likelihood. Originally designed for image classification, this elegant mathematical framework now achieves
CAR-T's $500K Quality Problem: Why the Most Expensive Therapy in Medicine Still Relies on Manual Flow Cytometry
CAR-T cell therapy costs $500K per dose with a 30-day manufacturing bottleneck. Flow cytometry QC — still largely manual — is the rate-limiting step. As next-day manufacturing emerges, AI-automated an
Cytek Biosciences at the AI Crossroads: Why a $200M Spectral Cytometry Leader Needs Agentic Partners
Cytek Biosciences just posted record Q4 revenue but EBITDA collapsed 78%. With 3,664 instruments, 24K Cloud users, and zero AI announcements, the spectral cytometry pioneer faces an existential softwa
Flow Monkey vs. The World: Why Every Flow Cytometry AI Tool Stops at Gating — and We Don't
We mapped every AI-powered flow cytometry tool on the market — FlowJo, OMIQ, AHEAD Cyto-copilot, UNITO, flowMagic, CellCNN, DeepCyTOF — and found they all solve the same problem: automated gating. Flo
AI Meets Spectral Flow Cytometry: How Machine Learning Is Transforming Immune Monitoring
Spectral flow cytometry generates unprecedented volumes of high-dimensional immune data. AI and machine learning are automating analysis, replacing subjective manual gating, and unlocking clinical ins
NIST's Flow Cytometry Standards Consortium Has 60 Members and a $25K Entry Fee. Here's Why It Might Be Worth It for AI Startups.
NIST's FCSC has 60 members including Pfizer, FDA, and your competitors. WG5 is building AI-ready reference datasets. If you're building AI for flow cytometry, this consortium determines what 'validate
The CAR-T Manufacturing Bottleneck: Why $500K Still Can't Guarantee a Cure
33% of lymphoma patients never receive their CAR-T infusion because manufacturing fails first. The root cause: a 4-marker QC system in a 36-marker world. Here's what I found when I went looking for an
The Fibrocyte Switch: When Severe Asthma Cells Stop Building Walls and Start Amplifying Inflammation
Spectral flow cytometry data from severe vs mild asthma fibrocytes reveals a dramatic phenotype switch: α-SMA drops 40% while Type 2 cytokines (IL-4/IL-5/IL-13) surge during 3-day culture. Supported b
The CAR-T Quality Blind Spot: Why $500K Therapies Still Fail Half the Time
CAR-T therapy costs $500K per dose, yet fewer than 50% of patients achieve durable responses. 33% of lymphoma patients never reach infusion due to manufacturing failure. A 36-marker spectral flow cyto
PD-1 Doesn't Mean What You Think: The Cross-Cancer Paradox That Rewrites CAR-T Quality Control
PD-1 high on T cells predicts BETTER outcomes in lung cancer, melanoma, lymphoma, ovarian cancer, and CAR-T therapy. Not because exhaustion is good — but because PD-1 guards the stem-like progenitor p